IS8807A - Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það - Google Patents
Notkun á daptómýsíni og lyfjasamsetningar sem innihalda þaðInfo
- Publication number
- IS8807A IS8807A IS8807A IS8807A IS8807A IS 8807 A IS8807 A IS 8807A IS 8807 A IS8807 A IS 8807A IS 8807 A IS8807 A IS 8807A IS 8807 A IS8807 A IS 8807A
- Authority
- IS
- Iceland
- Prior art keywords
- daptomycin
- administering
- muscle toxicity
- skeletal muscle
- effective amount
- Prior art date
Links
- 108010013198 Daptomycin Proteins 0.000 title abstract 6
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title abstract 6
- 229960005484 daptomycin Drugs 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 231100000483 muscle toxicity Toxicity 0.000 abstract 6
- 210000002027 skeletal muscle Anatomy 0.000 abstract 4
- 108010028921 Lipopeptides Proteins 0.000 abstract 2
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 abstract 2
- 229940052337 quinupristin/dalfopristin Drugs 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10182898P | 1998-09-25 | 1998-09-25 | |
| US12575099P | 1999-03-24 | 1999-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8807A true IS8807A (is) | 2009-03-10 |
Family
ID=26798675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS5890A IS5890A (is) | 1998-09-25 | 2001-03-14 | Aðferð til að gefa sýklalyf |
| IS8807A IS8807A (is) | 1998-09-25 | 2009-03-10 | Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS5890A IS5890A (is) | 1998-09-25 | 2001-03-14 | Aðferð til að gefa sýklalyf |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6468967B1 (is) |
| EP (2) | EP1674107B8 (is) |
| JP (4) | JP4184607B2 (is) |
| KR (2) | KR20100051735A (is) |
| CN (2) | CN1150029C (is) |
| AT (1) | ATE322280T1 (is) |
| AU (1) | AU764348B2 (is) |
| BR (1) | BR9914051A (is) |
| CA (1) | CA2344318C (is) |
| CY (3) | CY1105556T1 (is) |
| DE (3) | DE122006000049I1 (is) |
| DK (2) | DK1674107T3 (is) |
| ES (2) | ES2259845T3 (is) |
| HK (1) | HK1040363B (is) |
| HU (1) | HU230656B1 (is) |
| IS (2) | IS5890A (is) |
| LU (1) | LU91254I2 (is) |
| NL (1) | NL300232I2 (is) |
| NO (1) | NO20011454L (is) |
| NZ (1) | NZ510690A (is) |
| PL (2) | PL206091B1 (is) |
| PT (2) | PT1674107T (is) |
| RU (1) | RU2363489C9 (is) |
| SI (2) | SI1115417T1 (is) |
| TR (1) | TR200100841T2 (is) |
| WO (1) | WO2000018419A2 (is) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9914051A (pt) | 1998-09-25 | 2001-06-19 | Cubist Pharm Inc | Métodos para administração de antibióticos |
| IL150223A0 (en) | 1999-12-15 | 2002-12-01 | Cubist Pharm Inc | Lipopeptides and pharmaceutical compositions containing the same |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| KR20080036661A (ko) * | 2000-12-18 | 2008-04-28 | 큐비스트 파마슈티컬즈 인코포레이티드 | 정제된 리포펩티드의 제조 방법 |
| EP1932853A1 (en) | 2001-08-06 | 2008-06-18 | Cubist Pharmaceutical Inc. | Novel depsipeptides and process for preparing same |
| WO2004017925A2 (en) * | 2002-08-23 | 2004-03-04 | Genome Therapeutics Corporation | Methods and reagents for preventing bacteremias |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050277581A1 (en) * | 2002-11-18 | 2005-12-15 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050220862A1 (en) | 2004-03-31 | 2005-10-06 | Bernstein Joel E | Compositions with reduced hepatotoxicity |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| US20080051326A1 (en) * | 2004-11-12 | 2008-02-28 | Alexander Dylan C | Antiinfective Lipopeptides |
| US8524734B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070238630A1 (en) * | 2006-03-29 | 2007-10-11 | Phillips Douglas H | Subcutaneous skin cleanser |
| EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| TW200940552A (en) * | 2008-03-04 | 2009-10-01 | Elan Pharm Inc | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| EP2320933B1 (en) | 2008-07-17 | 2017-12-27 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
| KR20160150110A (ko) | 2008-10-07 | 2016-12-28 | 랩터 파마슈티컬스 인코포레이티드 | 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형 |
| US8629139B2 (en) | 2008-10-07 | 2014-01-14 | Mpex Pharmaceuticals, Inc. | Topical use of Levofloxacin for reducing lung inflammation |
| US8809263B2 (en) | 2008-10-24 | 2014-08-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Anti-infective hydroxy-phenyl-benzoates and methods of use |
| CN102325787B (zh) | 2008-12-22 | 2014-05-28 | 丘比斯特药物股份有限公司 | 治疗革兰氏阳性感染的新的抗菌剂 |
| US8343912B2 (en) | 2008-12-23 | 2013-01-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2011008193A1 (en) * | 2009-07-13 | 2011-01-20 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| US8450300B2 (en) * | 2009-07-13 | 2013-05-28 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| LT2473170T (lt) | 2009-09-04 | 2019-10-10 | Horizon Orphan Llc | Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui |
| DK2504353T4 (da) | 2009-11-23 | 2023-11-20 | Cubist Pharmaceuticals Llc | Lipopeptidsammensætninger og tilsvarende fremgangsmåder |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2013059610A1 (en) | 2011-10-20 | 2013-04-25 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| JP2015514095A (ja) | 2012-03-30 | 2015-05-18 | キュービスト ファーマシューティカルズ， インコーポレイテッド | １，３，４−オキサジアゾールおよび１，３，４−チアジアゾールβ−ラクタマーゼ阻害剤 |
| BR112015005400B1 (pt) * | 2012-09-11 | 2022-03-08 | Hospira Australia Pty Ltd | Formulação de daptomicina liofilizada, formulação de daptomicina reconstituída, método para tratar um biofilme e método para preparar uma formulação de daptomicina liofilizada |
| CN103006562B (zh) * | 2013-01-21 | 2014-09-17 | 西南大学 | 达托霉素醇质体制剂 |
| US12036219B2 (en) | 2013-03-15 | 2024-07-16 | Melinta Subsidiary Corp. | Methods of treating infections in overweight and obese patients using antibiotics |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| CA3021745A1 (en) * | 2016-05-13 | 2017-11-16 | Spero Potentiator, Inc. | Potentiation of antibiotic activity by a novel cationic peptide, spr741 |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
| CA2011365A1 (en) | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| FR2755857B1 (fr) | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
| FR2772272B1 (fr) * | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| BR9914051A (pt) | 1998-09-25 | 2001-06-19 | Cubist Pharm Inc | Métodos para administração de antibióticos |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
-
1999
- 1999-09-24 BR BR9914051-9A patent/BR9914051A/pt not_active Application Discontinuation
- 1999-09-24 SI SI9930904T patent/SI1115417T1/sl unknown
- 1999-09-24 AT AT99949913T patent/ATE322280T1/de active
- 1999-09-24 NZ NZ510690A patent/NZ510690A/xx not_active IP Right Cessation
- 1999-09-24 TR TR2001/00841T patent/TR200100841T2/xx unknown
- 1999-09-24 PL PL384274A patent/PL206091B1/pl unknown
- 1999-09-24 DE DE1999630758 patent/DE122006000049I1/de active Pending
- 1999-09-24 JP JP2000571937A patent/JP4184607B2/ja not_active Expired - Lifetime
- 1999-09-24 SI SI9931082A patent/SI1674107T1/sl unknown
- 1999-09-24 EP EP06006697.4A patent/EP1674107B8/en not_active Expired - Lifetime
- 1999-09-24 DE DE69930758T patent/DE69930758T2/de not_active Expired - Lifetime
- 1999-09-24 DK DK06006697.4T patent/DK1674107T3/en active
- 1999-09-24 KR KR1020107006807A patent/KR20100051735A/ko not_active Ceased
- 1999-09-24 PT PT60066974T patent/PT1674107T/pt unknown
- 1999-09-24 CN CNB998124982A patent/CN1150029C/zh not_active Ceased
- 1999-09-24 CA CA002344318A patent/CA2344318C/en not_active Expired - Lifetime
- 1999-09-24 US US09/406,568 patent/US6468967B1/en not_active Expired - Lifetime
- 1999-09-24 DK DK99949913T patent/DK1115417T3/da active
- 1999-09-24 HK HK02100152.2A patent/HK1040363B/en not_active IP Right Cessation
- 1999-09-24 ES ES99949913T patent/ES2259845T3/es not_active Expired - Lifetime
- 1999-09-24 ES ES06006697.4T patent/ES2603086T3/es not_active Expired - Lifetime
- 1999-09-24 PT PT99949913T patent/PT1115417E/pt unknown
- 1999-09-24 CN CNA200410031708XA patent/CN1530136A/zh active Pending
- 1999-09-24 HU HU0103874A patent/HU230656B1/hu unknown
- 1999-09-24 PL PL348328A patent/PL203689B1/pl unknown
- 1999-09-24 WO PCT/US1999/022366 patent/WO2000018419A2/en active IP Right Grant
- 1999-09-24 DE DE200612000049 patent/DE122006000049I2/de active Active
- 1999-09-24 AU AU62687/99A patent/AU764348B2/en not_active Expired
- 1999-09-24 KR KR1020017003735A patent/KR20010075327A/ko not_active Ceased
- 1999-09-24 EP EP99949913A patent/EP1115417B1/en not_active Revoked
-
2001
- 2001-03-14 IS IS5890A patent/IS5890A/is unknown
- 2001-03-22 NO NO20011454A patent/NO20011454L/no not_active Application Discontinuation
-
2002
- 2002-02-20 US US10/082,544 patent/US6852689B2/en not_active Expired - Lifetime
-
2003
- 2003-05-27 JP JP2003149968A patent/JP2003321389A/ja not_active Withdrawn
-
2004
- 2004-03-04 RU RU2004106569/14A patent/RU2363489C9/ru active
- 2004-08-17 JP JP2004237765A patent/JP2004339238A/ja not_active Withdrawn
-
2006
- 2006-04-18 CY CY20061100536T patent/CY1105556T1/el unknown
- 2006-06-23 NL NL300232C patent/NL300232I2/nl unknown
- 2006-06-28 LU LU91254C patent/LU91254I2/fr unknown
- 2006-07-18 CY CY200600003C patent/CY2006003I2/el unknown
- 2006-09-22 JP JP2006258107A patent/JP2006335773A/ja not_active Withdrawn
-
2009
- 2009-03-10 IS IS8807A patent/IS8807A/is unknown
-
2016
- 2016-11-24 CY CY20161101219T patent/CY1118334T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8807A (is) | Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| AU2003301190A8 (en) | Administration of capsaicinoids | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| ZA943744B (en) | Therapeutic substituted guanidines | |
| DK0583421T3 (da) | Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| HUP0000110A2 (hu) | Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények | |
| GEP20043377B (en) | Pharmaceutical Complex | |
| SE0203817D0 (sv) | New composition | |
| GEP20053512B (en) | S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders. | |
| SE9803623D0 (sv) | New therapeutic application | |
| GB9211277D0 (en) | Pharmaceutical compositions |